Nature Communications (Sep 2020)
Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma
- Hsiang-chi Tseng,
- Wei Xiong,
- Saiaditya Badeti,
- Yan Yang,
- Minh Ma,
- Ting Liu,
- Carlos A. Ramos,
- Gianpietro Dotti,
- Luke Fritzky,
- Jie-gen Jiang,
- Qing Yi,
- James Guarrera,
- Wei-Xing Zong,
- Chen Liu,
- Dongfang Liu
Affiliations
- Hsiang-chi Tseng
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Wei Xiong
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Saiaditya Badeti
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Yan Yang
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Minh Ma
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Ting Liu
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Carlos A. Ramos
- Department of Medicine, Baylor College of Medicine, One Baylor Plaza
- Gianpietro Dotti
- Department of Microbiology and Immunology and Lineberger Comprehensive Cancer Center, University of North Carolina
- Luke Fritzky
- Imaging core facility, Rutgers University-New Jersey Medical School
- Jie-gen Jiang
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Qing Yi
- Center for Translational Research in Hematologic Malignancies, Houston Methodist Cancer Center, Houston Methodist Research Institute
- James Guarrera
- Department of Surgery, New Jersey Medical School, Rutgers-The State University of New Jersey
- Wei-Xing Zong
- School of Pharmacy, Rutgers-The State University of New Jersey
- Chen Liu
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- Dongfang Liu
- Department of Pathology, Immunology and Laboratory Medicine, Rutgers University-New Jersey Medical School
- DOI
- https://doi.org/10.1038/s41467-020-18444-2
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 15
Abstract
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in vitro and in vivo.
